PSMA Imaging Agent for Prostate Cancer Market Report – Research, Industry Analysis Reports and Market Demands

Global PSMA Imaging Agent for Prostate Cancer Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global PSMA Imaging Agent for Prostate Cancer Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 68Ga
- 1.3.3 18F
1.4 Market Analysis by Core Carrier Materials
- 1.4.1 Overview: Global PSMA Imaging Agent for Prostate Cancer Consumption Value by Core Carrier Materials: 2021 Versus 2025 Versus 2032
- 1.4.2 First Generation
- 1.4.3 Second Generation
1.5 Market Analysis by Mechanism of Action
- 1.5.1 Overview: Global PSMA Imaging Agent for Prostate Cancer Consumption Value by Mechanism of Action: 2021 Versus 2025 Versus 2032
- 1.5.2 Active Targeting
- 1.5.3 Passive Targeting
1.6 Market Analysis by Application
- 1.6.1 Overview: Global PSMA Imaging Agent for Prostate Cancer Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Nuclear Medicine and Molecular Imaging
- 1.6.3 Precision Oncology Diagnostics
- 1.6.4 Radiopharmaceuticals and Radiopharmaceuticals
1.7 Global PSMA Imaging Agent for Prostate Cancer Market Size & Forecast
- 1.7.1 Global PSMA Imaging Agent for Prostate Cancer Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global PSMA Imaging Agent for Prostate Cancer Sales Quantity (2021-2032)
- 1.7.3 Global PSMA Imaging Agent for Prostate Cancer Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: PSMA Imaging Agent for Prostate Cancer by Manufacturer

3.1 Global PSMA Imaging Agent for Prostate Cancer Sales Quantity by Manufacturer (2021-2026)
3.2 Global PSMA Imaging Agent for Prostate Cancer Revenue by Manufacturer (2021-2026)
3.3 Global PSMA Imaging Agent for Prostate Cancer Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of PSMA Imaging Agent for Prostate Cancer by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 PSMA Imaging Agent for Prostate Cancer Manufacturer Market Share in 2025
- 3.4.3 Top 6 PSMA Imaging Agent for Prostate Cancer Manufacturer Market Share in 2025
3.5 PSMA Imaging Agent for Prostate Cancer Market: Overall Company Footprint Analysis
- 3.5.1 PSMA Imaging Agent for Prostate Cancer Market: Region Footprint
- 3.5.2 PSMA Imaging Agent for Prostate Cancer Market: Company Product Type Footprint
- 3.5.3 PSMA Imaging Agent for Prostate Cancer Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global PSMA Imaging Agent for Prostate Cancer Market Size by Region
- 4.1.1 Global PSMA Imaging Agent for Prostate Cancer Sales Quantity by Region (2021-2032)
- 4.1.2 Global PSMA Imaging Agent for Prostate Cancer Consumption Value by Region (2021-2032)
- 4.1.3 Global PSMA Imaging Agent for Prostate Cancer Average Price by Region (2021-2032)
4.2 North America PSMA Imaging Agent for Prostate Cancer Consumption Value (2021-2032)
4.3 Europe PSMA Imaging Agent for Prostate Cancer Consumption Value (2021-2032)
4.4 Asia-Pacific PSMA Imaging Agent for Prostate Cancer Consumption Value (2021-2032)
4.5 South America PSMA Imaging Agent for Prostate Cancer Consumption Value (2021-2032)
4.6 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global PSMA Imaging Agent for Prostate Cancer Sales Quantity by Type (2021-2032)
5.2 Global PSMA Imaging Agent for Prostate Cancer Consumption Value by Type (2021-2032)
5.3 Global PSMA Imaging Agent for Prostate Cancer Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global PSMA Imaging Agent for Prostate Cancer Sales Quantity by Application (2021-2032)
6.2 Global PSMA Imaging Agent for Prostate Cancer Consumption Value by Application (2021-2032)
6.3 Global PSMA Imaging Agent for Prostate Cancer Average Price by Application (2021-2032)

7 North America

7.1 North America PSMA Imaging Agent for Prostate Cancer Sales Quantity by Type (2021-2032)
7.2 North America PSMA Imaging Agent for Prostate Cancer Sales Quantity by Application (2021-2032)
7.3 North America PSMA Imaging Agent for Prostate Cancer Market Size by Country
- 7.3.1 North America PSMA Imaging Agent for Prostate Cancer Sales Quantity by Country (2021-2032)
- 7.3.2 North America PSMA Imaging Agent for Prostate Cancer Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe PSMA Imaging Agent for Prostate Cancer Sales Quantity by Type (2021-2032)
8.2 Europe PSMA Imaging Agent for Prostate Cancer Sales Quantity by Application (2021-2032)
8.3 Europe PSMA Imaging Agent for Prostate Cancer Market Size by Country
- 8.3.1 Europe PSMA Imaging Agent for Prostate Cancer Sales Quantity by Country (2021-2032)
- 8.3.2 Europe PSMA Imaging Agent for Prostate Cancer Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific PSMA Imaging Agent for Prostate Cancer Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific PSMA Imaging Agent for Prostate Cancer Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific PSMA Imaging Agent for Prostate Cancer Market Size by Region
- 9.3.1 Asia-Pacific PSMA Imaging Agent for Prostate Cancer Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific PSMA Imaging Agent for Prostate Cancer Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America PSMA Imaging Agent for Prostate Cancer Sales Quantity by Type (2021-2032)
10.2 South America PSMA Imaging Agent for Prostate Cancer Sales Quantity by Application (2021-2032)
10.3 South America PSMA Imaging Agent for Prostate Cancer Market Size by Country
- 10.3.1 South America PSMA Imaging Agent for Prostate Cancer Sales Quantity by Country (2021-2032)
- 10.3.2 South America PSMA Imaging Agent for Prostate Cancer Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Market Size by Country
- 11.3.1 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa PSMA Imaging Agent for Prostate Cancer Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 PSMA Imaging Agent for Prostate Cancer Market Drivers
12.2 PSMA Imaging Agent for Prostate Cancer Market Restraints
12.3 PSMA Imaging Agent for Prostate Cancer Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of PSMA Imaging Agent for Prostate Cancer and Key Manufacturers
13.2 Manufacturing Costs Percentage of PSMA Imaging Agent for Prostate Cancer
13.3 PSMA Imaging Agent for Prostate Cancer Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 PSMA Imaging Agent for Prostate Cancer Typical Distributors
14.3 PSMA Imaging Agent for Prostate Cancer Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global PSMA Imaging Agent for Prostate Cancer market size was valued at US$ 1821 million in 2025 and is forecast to a readjusted size of US$ 2915 million by 2032 with a CAGR of 6.9% during review period.
In 2025, the global production of PSMA imaging agent for prostate cancer reached 3.5394 million units, with an average selling price of $500 per unit. The annual production capacity of PSMA imaging agents for prostate cancer worldwide is approximately 5 million units, with a gross margin of about 30.4%. PSMA imaging agent for prostate cancer is a radiotracer that targets prostate‑specific membrane antigen (PSMA) and enables molecular‑level imaging of prostate cancer lesions via positron emission tomography (PET). PSMA is highly expressed on the surface of prostate cancer cells. After the imaging agent specifically binds to it, PET/CT or PET/MRI equipment is used to detect radioactive signals, thereby enabling high‑sensitivity localization of primary lesions, detection of metastases, and assessment of recurrence. It is currently an important tool in precision diagnosis and treatment of prostate cancer. The upstream of PSMA imaging agents for prostate cancer includes radionuclides (such as gallium‑68, fluorine‑18, etc.), PSMA‑targeting ligands (small molecules/peptides/antibodies), and nanocarriers/chelators, among others. The midstream consists of manufacturers of PSMA imaging agents for prostate cancer, while the downstream is mainly used in nuclear medicine and molecular imaging, precision tumor diagnosis, and radiopharmaceuticals and nuclear medicine.
Currently, the market for PSMA imaging agent for prostate cancer is in a phase of rapid development. As a revolutionary molecular imaging tool, it has been widely integrated into clinical management pathways for prostate cancer, playing a key role especially in initial staging, detection of biochemical recurrence, and formulation of treatment strategies. With the growing availability of PET/CT and PET/MRI equipment and the continuous emergence of novel PSMA ligands, the clinical applications of this imaging agent are steadily expanding. Meanwhile, the rise of the theranostics concept means that PSMA imaging agents for prostate cancer are not only used for diagnosis but are also beginning to be linked with PSMA‑targeted radionuclide therapy, ushering prostate cancer into a new era of precision medicine. Furthermore, improvements in regulatory approval and standardized production requirements for radiopharmaceuticals, along with gradual optimization of reimbursement policies, have further contributed to the maturation and growth of this market.
Report Scope
This report is a detailed and comprehensive analysis for global PSMA Imaging Agent for Prostate Cancer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global PSMA Imaging Agent for Prostate Cancer market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global PSMA Imaging Agent for Prostate Cancer market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global PSMA Imaging Agent for Prostate Cancer market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global PSMA Imaging Agent for Prostate Cancer market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PSMA Imaging Agent for Prostate Cancer
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PSMA Imaging Agent for Prostate Cancer market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lantheus, Telix Pharmaceuticals, Novartis, Blue Earth Diagnostics（Bracco）, Sinotau, DC PHARMA, Clarity Pharmaceuticals, Hengrui Pharma, CRAND PHARMACEUTICAL, Norroy Bioscience, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
PSMA Imaging Agent for Prostate Cancer market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
68Ga
18F
Market segment by Core Carrier Materials
First Generation
Second Generation
Market segment by Mechanism of Action
Active Targeting
Passive Targeting
Market segment by Application
Nuclear Medicine and Molecular Imaging
Precision Oncology Diagnostics
Radiopharmaceuticals and Radiopharmaceuticals
Major players covered
Lantheus
Telix Pharmaceuticals
Novartis
Blue Earth Diagnostics（Bracco）
Sinotau
DC PHARMA
Clarity Pharmaceuticals
Hengrui Pharma
CRAND PHARMACEUTICAL
Norroy Bioscience
HUAYI RADIOPHARMACEUTICALS
Yunhe Pharma
C Ray Therapeutics
Curium Holding France S.A.S.
ABX advanced biochemical compounds GmbH
Isotopia Molecular Imaging Ltd.
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe PSMA Imaging Agent for Prostate Cancer product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PSMA Imaging Agent for Prostate Cancer, with price, sales quantity, revenue, and global market share of PSMA Imaging Agent for Prostate Cancer from 2021 to 2026.
Chapter 3, the PSMA Imaging Agent for Prostate Cancer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PSMA Imaging Agent for Prostate Cancer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and PSMA Imaging Agent for Prostate Cancer market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of PSMA Imaging Agent for Prostate Cancer.
Chapter 14 and 15, to describe PSMA Imaging Agent for Prostate Cancer sales channel, distributors, customers, research findings and conclusion.

Buy now